Compare AMBQ & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMBQ | VALN |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 594.9M | 495.5M |
| IPO Year | N/A | 2021 |
| Metric | AMBQ | VALN |
|---|---|---|
| Price | $81.66 | $5.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $42.20 | $15.50 |
| AVG Volume (30 Days) | ★ 735.5K | 19.9K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $41.81 | N/A |
| Revenue Next Year | $27.98 | $93.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.12 | $5.04 |
| 52 Week High | $91.61 | $12.25 |
| Indicator | AMBQ | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 51.24 | 42.47 |
| Support Level | $73.59 | $5.10 |
| Resistance Level | $88.50 | $5.52 |
| Average True Range (ATR) | 6.24 | 0.20 |
| MACD | -0.87 | 0.01 |
| Stochastic Oscillator | 47.07 | 18.00 |
Ambiq Micro Inc is a fabless semiconductor company that has developed technology based on a patented Sub-threshold Power Optimized Technology (SPOT) platform that significantly reduces the amount of power consumed by integrated circuits. It is a pioneer and provider of ultra-low power semiconductor solutions designed to address the significant power consumption challenges of general purpose and AI compute - especially at the edge.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.